Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer

Futoshi Kawamata, Hirofumi Kamachi, Takahiro Einama, Shigenori Homma, Munenori Tahara, Masaya Miyazaki, Shinya Tanaka, Toshiya Kamiyama, Hiroshi Nishihara, Akinobu Taketomi, Satoru Todo

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Mesothelin is expressed in various types of malignant tumors, and we recently reported that the expression of mesothelin was related to unfavorable patient outcome in pancreatic ductal adenocarcinoma and gastric adenocarcinoma. In this study, we examined the clinicopathological significance of mesothelin expression in extrahepatic bile duct cancer (EHBDCA), especially in terms of its association with the staining pattern. Tissue samples from 61 EHBDCA (16 hilar cholangiocarcinoma, 17 upper bile duct adenocarcinoma, 20 middle bile duct adenocarcinoma and 8 distal bile duct adenocarcinoma) were immunohistochemically examined. The expression levels of mesothelin in tumor cells was classified into the localization of mesothelin in luminal membrane and/or cytoplasm, in addition to high and low according to the staining intensity and proportion as a conventional analysis. 'High-level expression' of mesothelin (47.5%) was statistically correlated with liver metastasis (P=0.013) and poorer patient outcome (P=0.022), while 'luminal membrane positive' of mesothelin (52.5%) was more significantly correlated with liver metastasis (P=0.006), peritoneal metastasis (P=0.024) and unfavorable patient outcome (P=0.017). Moreover, we found that 'cytoplasmic expression' isolated from 'luminal membrane negative' of mesothelin represented the best patient prognosis throughout this study. We describe the expression pattern level of mesothelin, i.e., in luminal membrane or cytoplasm both high and low level, evidently indicate the patient prognosis of EHBDCA, suggesting the pivotal role of mesothelin in cancer promotion depending on its intracellular localization.

Original languageEnglish
Pages (from-to)2109-2118
Number of pages10
JournalInternational journal of oncology
Volume41
Issue number6
DOIs
Publication statusPublished - 2012 Dec 1
Externally publishedYes

Fingerprint

Bile Duct Neoplasms
Extrahepatic Bile Ducts
Adenocarcinoma
Bile Ducts
Membranes
Neoplasm Metastasis
Cytoplasm
Klatskin Tumor
mesothelin
Staining and Labeling
Neoplasms
Liver
Stomach

Keywords

  • Intracellular localization
  • Luminal membrane expression
  • Mesothelin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kawamata, F., Kamachi, H., Einama, T., Homma, S., Tahara, M., Miyazaki, M., ... Todo, S. (2012). Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. International journal of oncology, 41(6), 2109-2118. https://doi.org/10.3892/ijo.2012.1662

Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. / Kawamata, Futoshi; Kamachi, Hirofumi; Einama, Takahiro; Homma, Shigenori; Tahara, Munenori; Miyazaki, Masaya; Tanaka, Shinya; Kamiyama, Toshiya; Nishihara, Hiroshi; Taketomi, Akinobu; Todo, Satoru.

In: International journal of oncology, Vol. 41, No. 6, 01.12.2012, p. 2109-2118.

Research output: Contribution to journalArticle

Kawamata, F, Kamachi, H, Einama, T, Homma, S, Tahara, M, Miyazaki, M, Tanaka, S, Kamiyama, T, Nishihara, H, Taketomi, A & Todo, S 2012, 'Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer', International journal of oncology, vol. 41, no. 6, pp. 2109-2118. https://doi.org/10.3892/ijo.2012.1662
Kawamata, Futoshi ; Kamachi, Hirofumi ; Einama, Takahiro ; Homma, Shigenori ; Tahara, Munenori ; Miyazaki, Masaya ; Tanaka, Shinya ; Kamiyama, Toshiya ; Nishihara, Hiroshi ; Taketomi, Akinobu ; Todo, Satoru. / Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. In: International journal of oncology. 2012 ; Vol. 41, No. 6. pp. 2109-2118.
@article{9ddb6725d3d948e6bfe95a8088964a84,
title = "Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer",
abstract = "Mesothelin is expressed in various types of malignant tumors, and we recently reported that the expression of mesothelin was related to unfavorable patient outcome in pancreatic ductal adenocarcinoma and gastric adenocarcinoma. In this study, we examined the clinicopathological significance of mesothelin expression in extrahepatic bile duct cancer (EHBDCA), especially in terms of its association with the staining pattern. Tissue samples from 61 EHBDCA (16 hilar cholangiocarcinoma, 17 upper bile duct adenocarcinoma, 20 middle bile duct adenocarcinoma and 8 distal bile duct adenocarcinoma) were immunohistochemically examined. The expression levels of mesothelin in tumor cells was classified into the localization of mesothelin in luminal membrane and/or cytoplasm, in addition to high and low according to the staining intensity and proportion as a conventional analysis. 'High-level expression' of mesothelin (47.5{\%}) was statistically correlated with liver metastasis (P=0.013) and poorer patient outcome (P=0.022), while 'luminal membrane positive' of mesothelin (52.5{\%}) was more significantly correlated with liver metastasis (P=0.006), peritoneal metastasis (P=0.024) and unfavorable patient outcome (P=0.017). Moreover, we found that 'cytoplasmic expression' isolated from 'luminal membrane negative' of mesothelin represented the best patient prognosis throughout this study. We describe the expression pattern level of mesothelin, i.e., in luminal membrane or cytoplasm both high and low level, evidently indicate the patient prognosis of EHBDCA, suggesting the pivotal role of mesothelin in cancer promotion depending on its intracellular localization.",
keywords = "Intracellular localization, Luminal membrane expression, Mesothelin",
author = "Futoshi Kawamata and Hirofumi Kamachi and Takahiro Einama and Shigenori Homma and Munenori Tahara and Masaya Miyazaki and Shinya Tanaka and Toshiya Kamiyama and Hiroshi Nishihara and Akinobu Taketomi and Satoru Todo",
year = "2012",
month = "12",
day = "1",
doi = "10.3892/ijo.2012.1662",
language = "English",
volume = "41",
pages = "2109--2118",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer

AU - Kawamata, Futoshi

AU - Kamachi, Hirofumi

AU - Einama, Takahiro

AU - Homma, Shigenori

AU - Tahara, Munenori

AU - Miyazaki, Masaya

AU - Tanaka, Shinya

AU - Kamiyama, Toshiya

AU - Nishihara, Hiroshi

AU - Taketomi, Akinobu

AU - Todo, Satoru

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Mesothelin is expressed in various types of malignant tumors, and we recently reported that the expression of mesothelin was related to unfavorable patient outcome in pancreatic ductal adenocarcinoma and gastric adenocarcinoma. In this study, we examined the clinicopathological significance of mesothelin expression in extrahepatic bile duct cancer (EHBDCA), especially in terms of its association with the staining pattern. Tissue samples from 61 EHBDCA (16 hilar cholangiocarcinoma, 17 upper bile duct adenocarcinoma, 20 middle bile duct adenocarcinoma and 8 distal bile duct adenocarcinoma) were immunohistochemically examined. The expression levels of mesothelin in tumor cells was classified into the localization of mesothelin in luminal membrane and/or cytoplasm, in addition to high and low according to the staining intensity and proportion as a conventional analysis. 'High-level expression' of mesothelin (47.5%) was statistically correlated with liver metastasis (P=0.013) and poorer patient outcome (P=0.022), while 'luminal membrane positive' of mesothelin (52.5%) was more significantly correlated with liver metastasis (P=0.006), peritoneal metastasis (P=0.024) and unfavorable patient outcome (P=0.017). Moreover, we found that 'cytoplasmic expression' isolated from 'luminal membrane negative' of mesothelin represented the best patient prognosis throughout this study. We describe the expression pattern level of mesothelin, i.e., in luminal membrane or cytoplasm both high and low level, evidently indicate the patient prognosis of EHBDCA, suggesting the pivotal role of mesothelin in cancer promotion depending on its intracellular localization.

AB - Mesothelin is expressed in various types of malignant tumors, and we recently reported that the expression of mesothelin was related to unfavorable patient outcome in pancreatic ductal adenocarcinoma and gastric adenocarcinoma. In this study, we examined the clinicopathological significance of mesothelin expression in extrahepatic bile duct cancer (EHBDCA), especially in terms of its association with the staining pattern. Tissue samples from 61 EHBDCA (16 hilar cholangiocarcinoma, 17 upper bile duct adenocarcinoma, 20 middle bile duct adenocarcinoma and 8 distal bile duct adenocarcinoma) were immunohistochemically examined. The expression levels of mesothelin in tumor cells was classified into the localization of mesothelin in luminal membrane and/or cytoplasm, in addition to high and low according to the staining intensity and proportion as a conventional analysis. 'High-level expression' of mesothelin (47.5%) was statistically correlated with liver metastasis (P=0.013) and poorer patient outcome (P=0.022), while 'luminal membrane positive' of mesothelin (52.5%) was more significantly correlated with liver metastasis (P=0.006), peritoneal metastasis (P=0.024) and unfavorable patient outcome (P=0.017). Moreover, we found that 'cytoplasmic expression' isolated from 'luminal membrane negative' of mesothelin represented the best patient prognosis throughout this study. We describe the expression pattern level of mesothelin, i.e., in luminal membrane or cytoplasm both high and low level, evidently indicate the patient prognosis of EHBDCA, suggesting the pivotal role of mesothelin in cancer promotion depending on its intracellular localization.

KW - Intracellular localization

KW - Luminal membrane expression

KW - Mesothelin

UR - http://www.scopus.com/inward/record.url?scp=84869773333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869773333&partnerID=8YFLogxK

U2 - 10.3892/ijo.2012.1662

DO - 10.3892/ijo.2012.1662

M3 - Article

VL - 41

SP - 2109

EP - 2118

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -